The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia

Blood

Volumn 106, Issue 2, 2005, Pages 650-657

  Oppezzo, Pablo ^b   Vasconcelos, Yuri ^b   Settegrana, Catherine ^b   Jeannel, Dominique ^b   Vuillier, Françoise ^b   Legarff Tavernier, Magali ^b   Kimura, Eliza Yuriko ^b   Bechet, Stéphane ^b   Dumas, Gérard ^b   Brissard, Martine ^b   Merle Béral, Hélène ^b   Yamamoto, Mihoko ^b   Dighiero, Guillaume ^b   Davi, Frédéric ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MESSENGER RNA; PROTEIN ADAM29; PROTEIN KINASE ZAP 70; PROTEIN LPL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DNA MICROARRAY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IGVH GENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TREATMENT OUTCOME;

EID: 22144480303     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3344     Document Type: Article

References (39)

1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
2. Binet JL, Lepoprier M, Dighiero G, et al. Aclinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer. 1977;40:855-864.
3. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998;338:1506-1514.
4. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999;93:1732-1737.
5. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood. 1996;88:4259-4264.
6. Magnac C, Porcher R, Davi F, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia. 2003;17:133-137.
7. Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? Hematol J. 2002;3:7-9.
8. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
9. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023-1029.
10. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003;101:1262-1269.
11. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
12. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
13. Dyer MJ, Oscier DG. The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. Leukemia. 2002;16:973-984.
14. Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288-294.
15. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
16. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
17. Maloum K, Davi F, Merle-Beral H, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood. 2000;96:377-379.
18. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
19. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
20. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
21. Durig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia. 2003;17:2426-2434.
22. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105-111.
23. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
24. Vasconcelos Y, de Vos J, Vallat L, et al. Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with aggressive disease and unmutated Ig genes. Leukemia. In press.
25. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SNS (CD79b). Am J Clin Pathol. 1997;108:378-382.
26. Pritsch O, Troussard X, Magnac C, et al. VH gene usage by family members affected with chronic lymphocytic leukaemia. Br J Haematol. 1999;107:616-624.
27. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
28. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
29. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med. 2002;80:753-769.
30. Preiss-Landl K, Zimmermann R, Hammerle G, Zechner R. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol. 2002;13:471-481.
31. Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther. 1996;70:101-135.
32. de Sanctis JB, Blanca I, Radzioch D, Bianco NE. Lipoprotein lipase expression in natural killer cells and its role in their cytotoxic activity. Immunology. 1994;83:232-239.
33. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609-4614.
34. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:1087-1093.
35. Pierce SK. Lipid rafts and B-cell activation. Nat Rev Immunol. 2002;2:96-105.
36. Yamamoto S, Higuchi S, Yoshiyama K, et al. ADAM family proteins in the immune system. Immunol Today. 1999;20:278-284.
37. Primakoff P, Myles DG. The ADAM gene family, surface proteins with adhesion and protease activity. Trends Genet. 2000;16:83-87.
38. Cerretti DP, DuBose RF, Black RA, Nelson N. Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. Biochem Biophys Res Commun. 1999;263:810-815.
39. Xu R, Cai J, Xu T, et al. Molecular cloning and mapping of a novel ADAM gene (ADAM29) to human chromosome 4. Genomics. 1999;62:537-539.